Scientific breakthroughs during the pandemic are driving a lot of optimism around mRNA technology, leading to billion dollar collaboration deals for biotechs with global pharma companies. With ongoing development efforts seeing promise against old enemies such as HIV and infinite possibilities for cancers, autoimmune diseases, genetic diseases and beyond, how should the industry apply this early victory into successful mRNA-based therapeutics and vaccines in these new disease settings? Come join this panel of notable industry experts discuss current market trends, share insights to what's being considered for mRNA technology and give guidance on what to look for in a partner.